The CML Advocates Network is both a virtual network and internet platform for patient organisations supporting patients and relatives affected by Chronic Myeloid Leukaemia (CML). Launched in 2007 with 4 founding member groups, it has now grown to more than 128 leukaemia patient groups in more than 93 countries on all continents, offering support by sharing of best practice, information and advice for CML patient representatives.

Read more

Professor Fréderic Millot University of Poitiers, Poitiers (France)

Read more

Please see below for a selection of interesting articles on pediatric CML in peer-reviewed journals.
Latest publications include:

• Recent progress in the management of pediatric chronic myeloid leukemia
  Shima H & Shimada H. Int J Hematol, February 2023 – open access publication
• Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro
  Eckart F et al. Hamostaseologie, January 2023 (epub ahead of print)
• Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan
  Liu HC et al. Br J Cancer, January 2023 (epub ahead of print)
• Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants
  Hoch M et al. Clin Pharmacol Drug Dev, January 2023 (epub ahead of print) – open access publication
• Alterations in cellular metabolism after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review
  Li C et al. Front Oncol, December 2022 – open access publication
• Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  Nishiyama-Fujita Y et al. Ann Med, December 2022 – open access publication
• Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course
  Delehaye F et al. Ann Hematol, November 2022 (epub ahead of print)
• Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment
  Karadas N et al. Int J Hematol, November 2022 (epub ahead of print)
• Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia
  Schleicher O et al. Front Oncol. September 2022 – open access publication
• Outcome of pediatric chronic myeloid leukemia with management focusing on gene transcript levels
  Al-Ghamlas I et al. Int J Pediatr Adolesc Med, September 2022 – open access publication
  

Search here for more publications on pediatric CML

• Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations – Review
  (Sembill S et al. Leukemia, January 2023) (epub ahead of print) – open access publication
• Management of chronic myeloid leukemia in childen and adolescents:
  Recommendations from the Children's Oncology Group CML Working Group
  (Athale U et al. Pediatr Blood Cancer, September 2019) - open access publication
• Managing children with CML: Pediatric CML guidelines IBFM
  (Fuente J et al. Br J Haematology, July 2014)

See here for more general guidelines on the management of CML

• Recent progress in the management of pediatric chronic myeloid leukemia – Review
  (Shima H and Shimada H. Int J Hematol, December 2022) (epub ahead of print)
• Chronic myeloid leukemia in children: immune function and vaccinations
  (Suttorp M et al. J Clin Med, September 2021) - open access publication
• Management of pediatric leukemia (in French)
  (Héritier S et al. Soins Pediatr Peuric, May-June 201)
• Tyrosine kinase inhibitors and beyond for chronic myeloid leukemia in children
  (Phillips LN and Hijiya N. Pediatr Drugs, May 2021)
• Chronic myelogenous leukemia in childhood
  (Smith SM et al. Curr Oncol Rep, March 2021)
• Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia
  Suttorp M et al. Cancers(Basel), February 2021 - open access publication
• Features and outcomes of chronic myeloid leukemia at very young age:
  Data from the International Pediatric Registry
  (Meral Günes A et al. Pediatr Blood Cancer, January 2021)
• Horn of plenty: Value of the International registry fore pediatric chronic myeloid leukemia
  (Suttorp M et al. World J Clin Oncol, June 2020) - open access publication
• How I treat chronic myeloid leukemia in children and adolescents
  (Hijiya N and Suttorp M. Blood, May 2019) - open access publication
• Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions 
  (Hijiya N et al. Pediatr Clin North Am, February 2016)
• Chronic myeloid leukemia in children is a unique disease that requires a different approach 
  (Hijiya N et al. Blood, October 2015)

Our 'Clinical Case Discussion Forum' features a number of discussions on pediatric CML cases. If you are a physician treating pediatric CML patients, please join our forum and get in touch with other experts.

The latest postings on pediatric CML include:

• 24 y female / CML-AP - 11 yr/3 TKI+ (T315I mut.) I treatment after ponatinb
  • Last post by Michael Deininger
• CML in younger patients in low socio-economic areas
  • Last post by Nasir Ahmad
• Challenging case - male 20 yrs old
  • Last post by Giuseppe Saglio
• Outcomes in children born to males on nilotinib
  • Last post by Jane Apperley
• 22 year old with no MMR after 3+ yrs on dasatinib
  • Last post by Timothy Hughes
• Ponatinib dose for pediatric patients
  • Last post by Nobuko Hijiya
• CML under 18 years old
  • Last post by Meinolf Suttorp
• 2nd transplant for 16 year old boy
  • last post by Timothy Hughes 
• Child with CML on dasatinib rising quant PCR
  • Last post by Guiseppe Saglio

A number of clinical trials and research activities are currently ongoing to research pediatric CML.
Find more information here.